

Peanut Allergy - Pipeline Insight, 2021

<https://marketpublishers.com/r/P1C95947074EN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P1C95947074EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Peanut Allergy - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Peanut Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Peanut Allergy Understanding

Peanut Allergy: Overview

A peanut allergy is a reaction that occurs when your body mistakenly identifies peanuts as harmful substances. When you eat peanuts or food containing peanuts, your immune system—the body's natural defense system that fights infections and diseases—overreacts and can cause a serious, even life-threatening response. Symptoms of peanut allergy can range from mild to severe. If you have a mild reaction, you may get a stomachache, a runny nose, itchy eyes, hives, or tingling in your lips or tongue. Your symptoms may start from within a few minutes to a few hours after eating peanuts or peanut products.

'Peanut Allergy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Peanut Allergy pipeline landscape is provided which includes the disease overview and Peanut Allergy treatment guidelines. The assessment part of the report embraces, in depth Peanut Allergy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peanut Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peanut Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Peanut Allergy.

Peanut Allergy Emerging Drugs Chapters

This segment of the Peanut Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peanut Allergy Emerging Drugs

Viaskin Peanut: DBV Technologies

DBV is developing the Viaskin technology platform, which delivers biologically active compounds, including allergens, via intact skin. Viaskin is an electrostatic patch, based on Epicutaneous Immunotherapy, or EPIT®, which administers an allergen directly onto the superficial layers of the skin to activate the immune system by specifically targeting antigen-presenting cells without allowing passage of the antigen into the bloodstream. It is currently in preregistration stage of development.

Dupilumab: Regeneron Pharmaceuticals/Sanofi

Dupilumab is a IL-4R Antibody that is being developed by Regeneron Pharmaceuticals in collaboration with Sanofi for the treatment of Peanut Allergy. It is currently in phase II stage of development.

CNP-201: Cour Pharmaceutical

CNP-201 is a biodegradable nanoparticle encapsulating peanut protein. It has the potential to treat patients with peanut allergy by reducing the need for strict peanut avoidance and reducing the potentially fatal health risks associated with peanut allergy. It is currently in phase I/II stage of development.

Further product details are provided in the report.....

Peanut Allergy: Therapeutic Assessment

This segment of the report provides insights about the different Peanut Allergy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peanut Allergy

There are approx. 15+ key companies which are developing the therapies for Peanut Allergy. The companies which have their Peanut Allergy drug candidates in the most advanced stage, i.e. preregistration include, DBV Technologies.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intradermal

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peanut Allergy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peanut Allergy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peanut Allergy drugs.

Peanut Allergy Report Insights

- Peanut Allergy Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Peanut Allergy Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Peanut Allergy drugs?

How many Peanut Allergy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peanut Allergy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peanut Allergy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Peanut Allergy and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

DBV Technologies

Regeneron Pharmaceuticals

Cour Pharmaceutical

HAL Allergy

InnoUp Farma S.L.

Vedanta Biosciences

Astellas Pharma

Intrimmune Therapeutics

Genentech

ASIT biotech

BlueWillow Biologics

Allergy Therapeutics

Alladapt Immunotherapeutics

Desentum

Camallergy

Prota Therapeutics

IgGenix

Key Products

Viaskin Peanut

Dupilumab

CNP-201

HAL MPE1

INP20

VE416

ASP0892

INT301

Omalizumab

pnt-ASIT+

Peanut-NE01 vaccine

Peanut SCIT

CA 002

PRT100

Contents

Introduction

Executive Summary

Peanut Allergy: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Preregistration)

Comparative Analysis

Viaskin Peanut: DBV Technologies

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Dupilumab: Regeneron Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

CNP-201: Cour Pharmaceutical

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
Comparative Analysis
Peanut-NE01 vaccine: BlueWillow Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
Comparative Analysis
Peanut Allergy Key Companies
Peanut Allergy Key Products
Peanut Allergy- Unmet Needs
Peanut Allergy- Market Drivers and Barriers
Peanut Allergy- Future Perspectives and Conclusion
Peanut Allergy Analyst Views
Peanut Allergy Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Peanut Allergy

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Peanut Allergy
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Peanut Allergy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P1C95947074EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P1C95947074EN.html>